SMA Europe receives funding from its member organisations, in the form of an annual membership fee and of voluntary donations towards our Call for Research Proposals. In addition, we receive funding from other non-profit organisations and from health sector corporates.
Our funders respect SMA Europe’s mission, strategy, independence, and integrity.
SMA Europe has adopted a code of practice for relationships with the pharmaceutical industry and all our funding partnerships are established with shared interest, transparency, trust, and mutual benefit.
For more information, please contact us at email@example.com.
Financial information 2021
In 2021 SMA Europe’s annual revenue was of € 904,696.69 while the organisation’s total annual expenses amounted to € 673 831,65.
Revenue received from health sector corporates
In 2021, SMA Europe received funding from 7 health sector corporate donors, amounting to a total of € 556,040.00.
The breakdown of each company’s donations is detailed in the graphic below.
SMA Europe appreciates the donations received from all its funders. Ensuring a sustained variety of funding is key to minimise potential conflicts of interest and to ensure the sustainability of the organisation.
SMA Europe would like to thank the following organisations for their highly valued support in 2021:
- SMA Europe’s member organisations
- Cure SMA
- LaCAR MDX Technologies
- Novartis Gene Therapies
- Wallac Oy